巨噬细胞移动抑制因子在非小细胞肺癌组织中表达的研究  

Research on the expressing of macrophage migration inhibitory factor in non-small cell lung carcinoma tissue

作　　者：赵劲松[1] 廖克龙[2] 杨康[2] 

机构地区：[1]解放军第42医院胸外科,四川乐山614100 [2]第三军医大学西南医院胸外科

出　　处：《中华临床医师杂志（电子版）》2012年第24期8123-8125,共3页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：目的研究巨噬细胞移动抑制因子(MIF)在非小细胞肺癌组织中的表达及意义。方法用免疫组化方法检测80例非小细胞肺癌标本和80例正常肺组织中MIF的表达水平。结果发现MIF在非小细胞肺癌组织中的表达较正常肺组织明显增加(阳性表达率:5%vs.88.7%,P<0.01),并与癌细胞的分化程度(P=0.019)、肿瘤的TNM分期(P=0.044)密切相关,MIF低表达组的5年生存率明显优于MIF高表达组(46%vs.15%,P<0.01)。结论 MIF在非小细胞肺癌的发病机制中可能起着重要的作用,可以作为非小细胞肺癌术前诊断、预后分析以及有潜在治疗价值的因子。Objective To investigate the expression and clinic significance of macrophage migration inhibitory factor(MIF)in non-small cell lung carcinoma(NSCLC)tissue.Methods To examine the expression level of MIF in eighty NSCLC specimens and normal lung tissue specimens by immunohistochemistry staining.Results MIF was overexpressed in NSCLC specimens sections(5% vs.88.7%,P<0.01),the expression of MIF close correlated with both tumor differentiation(P=0.019)and the tumor TNM staging(P=0.044).The survival rate of 5 years in low-MIF group was superior to high-MIF group(46% vs.15%,P<0.01).Conclusions MIF may play an important role in the pathogenesis of NSCLC and can be conducted as one index to preoperative diagnosis,pretest the prognosis of NSCLC and potential therapeutic value.

关 键 词：癌 非小细胞肺 巨噬细胞游走抑制因子 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]